Clostridium difficile infections among hospitalized children, United States, 1997-2006 von Zilberberg, Marya D, Tillotson, Glenn S, McDonald, Clifford

Volltext

The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities von Redell, Mark, Tillotson, Glenn S

Volltext

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-infer... von Vickers, Richard J, Dr, Tillotson, Glenn S, PhD, Nathan, Richard, MD, Hazan, Sabine, MD, Pullman, John, MD, Lucasti, Christopher, DO, Deck, Kenneth, MD, Yacyshyn, Bruce, Prof, Maliakkal, Benedict, MD, Pesant, Yves, MD, Tejura, Bina, MD, Roblin, David, Prof, Gerding, Dale N, Prof, Wilcox, Mark H, Prof

Volltext

Comment on: Community-acquired pneumonia: a US perspective on the guideline gap von Tillotson, Glenn S

Volltext

COUNTERPOINT: Do Randomized Controlled Trials Ignore Needed Patient Populations? No von Tillotson, Glenn S., PhD, FCCP

Volltext

Rebuttal From Dr Tillotson von Tillotson, Glenn S., PhD, FCCP

Volltext

Real-World Use of Oritavancin for the Treatment of Osteomyelitis von Scoble, Patrick J., Reilly, Joseph, Tillotson, Glenn S.

Volltext

Combating resistance while maintaining innovation: the future of antimicrobial stewardship von Vickers, Richard J, Bassetti, Matteo, Clancy, Cornelius J, Garey, Kevin W, Greenberg, David E, Nguyen, Minh-Hong, Roblin, David, Tillotson, Glenn S, Wilcox, Mark H

Volltext

The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Stud... von Estrada, Sandy, Lodise, Thomas P., Tillotson, Glenn S., Delaportas, Dino

Volltext

A new dawn for the management of influenza? von Tillotson, Glenn S

Volltext

Development of New Antibacterials: A Laudable Aim, But What Is the Value? von Tillotson, Glenn S.

Volltext

National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study von CRITCHLEY, Ian A, BROWN, Steven D, TRACZEWSKI, Maria M, TILLOTSON, Glenn S, JANJIC, Nebojsa

Volltext

Keeping the faith—reporting on antimicrobial resistance in an era of fake news von Tillotson, Glenn S

Volltext

The Controversy of Combination vs Monotherapy in the Treatment of Hospitalized Community-Acquired Pneumonia von Weiss, Karl, Tillotson, Glenn S

Volltext

FDA and the safe and appropriate antibiotic use of fluoroquinolones von Tillotson, Glenn S

Volltext

Trojan Horse Antibiotics-A Novel Way to Circumvent Gram-Negative Bacterial Resistance? von Tillotson, Glenn S.

Volltext

The Regulatory Pathway for Antifungal Drugs: A US Perspective von Tillotson, Joni, Tillotson, Glenn S.

Volltext

Difficult to Treat: Do We Need a New Definition? von Echols, Roger M., Tillotson, Glenn S.

Volltext

Antibiotic Development and the Evolving Role of Pharmacodynamics — As Good as It Gets? von Tillotson, Glenn S., Zinner, Stephen H.

Volltext

Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone von DuPont, Herbert L., DuPont, Andrew W., Tillotson, Glenn S.

Volltext